Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non …
K Izutsu, Y Minami, N Fukuhara, Y Terui, T Jo… - International Journal of …, 2020 - Springer
Patients with indolent non-Hodgkin lymphoma (iNHL) typically respond to first-line
immunochemotherapy, but relapse is common. Treatment options for relapsed iNHL include
chemotherapy±rituximab and rituximab monotherapy. Lenalidomide plus rituximab (R 2) is
an immunomodulatory regimen that enhances rituximab-mediated cytotoxicity and improves
clinical activity in iNHL. AUGMENT was a double-blind phase III randomized trial of R 2 vs.
rituximab+ placebo (R-placebo) in patients with relapsed/refractory follicular lymphoma or …
immunochemotherapy, but relapse is common. Treatment options for relapsed iNHL include
chemotherapy±rituximab and rituximab monotherapy. Lenalidomide plus rituximab (R 2) is
an immunomodulatory regimen that enhances rituximab-mediated cytotoxicity and improves
clinical activity in iNHL. AUGMENT was a double-blind phase III randomized trial of R 2 vs.
rituximab+ placebo (R-placebo) in patients with relapsed/refractory follicular lymphoma or …
[HTML][HTML] Subgroup analyses of elderly patients aged≥ 70 years in AUGMENT: A phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab plus …
M Trněný, JP Leonard, H Zhang, G Nowakowski… - Blood, 2019 - Elsevier
Background: The combination of lenalidomide+ rituximab (R 2) recently showed superior
efficacy vs R-placebo in patients (pts) with R/R iNHL (Leonard et al. J Clin Oncol 2019).
Based on these AUGMENT study results, R 2 was approved by the US FDA for treatment of
adult pts with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL).
Advanced age at diagnosis is a risk factor in pts with iNHL. We performed post-hoc
subgroup analyses by age from AUGMENT and data here focus on pts age≥ 70 y. Methods …
efficacy vs R-placebo in patients (pts) with R/R iNHL (Leonard et al. J Clin Oncol 2019).
Based on these AUGMENT study results, R 2 was approved by the US FDA for treatment of
adult pts with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL).
Advanced age at diagnosis is a risk factor in pts with iNHL. We performed post-hoc
subgroup analyses by age from AUGMENT and data here focus on pts age≥ 70 y. Methods …